Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion

NCT ID: NCT06383182

Last Updated: 2025-08-21

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-07-02
• Study Completion Date: 2026-12-30

Brief Summary

Acute ischaemic stroke (AIS) results in high rates of neurological morbidity and mortality, especially in patients with large vessel occlusion (LVO). Endovascular therapy (EVT) has been approved as the most effective treatment for patients with LVO , but about half patients undergoing EVT did not achieve good outcome. The mechanisms of poor prognosis are complex. How to accurately identify serological biomarkers related to patients' clinical prognosis is an important research topic nowadays.

Conditions

Ischemic Stroke

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

endovascular treatment

all patients with anterior circulation large vessel occlusion will receive endovascular treatment.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Age: 18-80 years;

2. Patients with acute anterior circulation large vessel occlusion within 24 hours of onset who will receive endovascular treatment;

3. Pre-stroke mRS: 0-1;

4. Baseline NIHSS: ≥6;

5. Signed informed consent.

Exclusion Criteria

1. The presence of contraindications to internal jugular vein cannulation;

2. Receiving intravenous thrombolysis;

3. Haemorrhagic stroke (cerebral haemorrhage or subarachnoid haemorrhage);

4. Coagulation disorders, systemic bleeding tendency, thrombocytopenia (<100×109/L);

5. Severe cardiac, hepatic or renal insufficiency (ALT or AST elevated more than 2 times the upper limit of normal value, or serum creatinine elevated more than 1.5 times the upper limit of normal value or in need of dialysis) or other serious medical diseases;

6. Severe uncontrolled hypertension (systolic blood pressure greater than 200 mmHg or diastolic blood pressure greater than 110 mmHg);

7. Pregnant or lactating women;

8. Other conditions who are not suitable for this trial by investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

General Hospital of Shenyang Military Region

OTHER

Sponsor Role: lead

Responsible Party

Hui-Sheng Chen

Director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

General Hospital of Northern Theater Command

Shenyang, , China

Site Status: RECRUITING

Countries

China

Facility Contacts

Zi-Ai Zhao

Role: primary

zhaoziai@hotmail.com

86-2428897517

Yu Cui

Role: backup

cuiyu.spu@hotmail.com

86-24-28897499

Other Identifiers

Y (2024) 054

Identifier Type: -

Identifier Source: org_study_id